{"id":"NCT00006400","sponsor":"National Heart, Lung, and Blood Institute (NHLBI)","briefTitle":"Hydroxyurea to Prevent Organ Damage in Children With Sickle Cell Anemia","officialTitle":"Pediatric Hydroxyurea Phase III Clinical Trial (BABY HUG)","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2000-08","primaryCompletion":"2009-09","completion":"2009-09","firstPosted":"2000-10-13","resultsPosted":"2020-08-19","lastUpdate":"2020-08-19"},"enrollment":193,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"PREVENTION"},"conditions":["Hematologic Diseases","Anemia, Sickle Cell"],"interventions":[{"type":"DRUG","name":"Hydroxyurea","otherNames":[]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"Hydroxyurea","type":"ACTIVE_COMPARATOR"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"The purpose of this study is to determine if hydroxyurea therapy is effective in the prevention of chronic end organ damage in pediatric patients with sickle cell anemia.","primaryOutcome":{"measure":"Treatment Differences of the Change in Qualitative Splenic Function From Baseline","timeFrame":"Before initiation of treatment and at 2 years","effectByArm":[{"arm":"Hydroxyurea","deltaMin":19,"sd":null},{"arm":"Placebo","deltaMin":28,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"0.21"}]},"eligibility":{"minAge":"9 Months","sex":"ALL","healthyVolunteers":false,"inclusionCount":1,"exclusionCount":13},"locations":{"siteCount":14,"countries":["United States"]},"refs":{"pmids":["15125610","19731330","21571150","18478575","19621454","19813252","19856395","19880138","20797449","21217080","23999955","22915643","22294512","22190441","21744485","21606305"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":19,"n":96},"commonTop":["UPPER RESPIRATORY INFECTION","FEVER >101.5 F (38.4 C)","Pain","Viral Syndrome","Otitis Media"]}}